喜保宁能有效治病吗？

Introduction: Sabril is a drug used to treat epilepsy. Its main ingredient is Vigabatrin. A generic version of Sabril already exists, and its efficacy is basically the same as that of the original drug. Patients should follow their doctor's recommendations and instructions for medication use to ensure the safety and effectiveness of treatment.

Generic version of Vigabatrin

On August 21, 2009, the US FDA approved Sabril as a monotherapy for pediatric patients aged 1 month to 2 years old, where the potential benefits of infantile spasms outweigh the potential risk of vision loss, and as an adjuvant (additional) treatment (CPS) for adult patients with refractory complex partial epilepsy. The currently known generic version is produced by Lucius Pharmaceuticals (Laos) Co., Ltd. It has been approved for sale by the Lao State Food and Drug Administration and has also been tested and certified by the Lao National Drug Control Institute.

Can the generic version of Vigabatrin also be effective in treating diseases?

Generic drugs must pass the review of the National Medical Products Administration and obtain an approval number before they can be put on the market. Therefore, the generic version of Vigabatrin that has gone through the formal approval process should be effective and safe in theory, such as the Laos Lucius version of Vigabatrin generic drug. However, illegal generic drugs may not have been formally approved, and their safety and effectiveness cannot be guaranteed, and their use may cause serious risks to health.

Price of Vigabatrin generic version

The price of Vigabatrin produced by Lucius in Laos is about 610$-800$, and the specification of a box is 500mg*100 tablets. The price of the generic version of Vigabatrin may vary due to a variety of factors, so the above prices are for reference only and should be subject to the actual price at the time of purchase.

The efficacy of Vigabatrin in treating epilepsy

Vigabatrin inhibits the activity of GABA transaminase and increases the level of γ-aminobutyric acid (GABA) in the brain, thereby exerting its anti-epileptic effect. Clinical trial data show that Vigabatrin can significantly reduce the frequency and duration of epileptic seizures and improve patients' quality of life and cognitive function.

Patients should also pay attention to its side effects when taking Vigabatrin, including headaches, fatigue, eye problems, etc. Patients should undergo regular vision examinations to monitor possible vision changes.